1. 1. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90(4): 1929-35. [ DOI:10.1210/jc.2004-1045] [ PMID] 2. 2. Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet. 2017; 296(3): 405-419. [ DOI:10.1007/s00404-017-4429-2] [ PMID] 3. 3. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber T, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009;161(4):575-82. [ DOI:10.1530/EJE-09-0432] [ PMID] 4. 4. Boulman, N et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2008; 89(5): 2160-5. [ DOI:10.1210/jc.2003-031096] [ PMID] 5. 5. Condorelli RA, Calogero AE, Di Mauro M, La Vignera S. PCOS and diabetes mellitus: from insulin resistance to altered beta pancreatic function, a link in evolution. Gynecological endocrinology: Gynecol Endocrinol. 2017:1-3 [ DOI:10.1080/09513590.2017.1342240] 6. 6. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2008; 83(5): 1454-60. [ DOI:10.1016/j.fertnstert.2004.11.070] [ PMID] 7. 7. Dumitrescu R, Mehedintu C, Briceag I, Purcarea V, Hudita D. The polycystic ovary syndrome: An update on metabolic and hormonal mechanisms.J Med Life . 2008;8(2): 142. 8. 8. González, F.Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012; 77(4): 300-5. [ DOI:10.1016/j.steroids.2011.12.003] [ PMID] [ PMCID] 9. 9. Holick MF, Chen TC. Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr. 2008; 87(4): 1080S-6S. [ PMID] 10. 10. Li HWR, Brereton RE, Anderson RA, Wallace AM, Ho CK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism. 2011;60(10):1475-81. [ DOI:10.1016/j.metabol.2011.03.002] [ PMID] 11. 11. Auwerx J, Bouillon R, Kesteloot H. Relation between 25-hydroxyvitamin D3, apolipoprotein AI, and high density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol. 1992;12(6):671-4. [ DOI:10.1161/01.ATV.12.6.671] 12. 12. Xiong, Y-l., Liang, X-y., Yang, X., Li, Y & Wei, L-n. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2011; 159(1): 148-50. [ DOI:10.1016/j.ejogrb.2011.07.012] [ PMID] 13. 13. Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis. 2008;18(7):511-8. [ DOI:10.1016/j.numecd.2008.05.004] [ PMID] 14. 14. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004;59(2):141-54. [ DOI:10.1097/01.OGX.0000109523.25076.E2] [ PMID] 15. 15. Gunning MN, Fauser B. Are women with polycystic ovary syndrome at increased cardiovascular disease risk later in life? Climacteric. 2017; 20(3):222-7. [ DOI:10.1080/13697137.2017.1316256] [ PMID] 16. 16. Dahlgren E, Janson P, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992;71(8):599-604. [ DOI:10.3109/00016349209006227] [ PMID] 17. 17. Morin G, Orlando V, Crites KS-M, Patey N, Mailhot G. Vitamin D attenuates inflammation in CFTR Knockdown Intestinal epithelial cells but has no effect in cells with intact CTFR. Am J Physiol Gastrointest Liver Physiol. ajpgi. 00060.2016;310 (8):539-549 18. 18. Ngo DT, Chan WP, Rajendran S, Heresztyn T, Amarasekera A, Sverdlov AL et al. Determinants of insulin responsiveness in young women: impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide. 2011; 25(3):326-30. [ DOI:10.1016/j.niox.2011.06.005] [ PMID] 19. 19. Orio Jr F, Palomba S, Spinelli L. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab.2004; 89(8): 3696-701. [ DOI:10.1210/jc.2003-032049] [ PMID] 20. 20. Moller D E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab. 2000; 11: 212-217. 21. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2003. 100:7265-7270. 21. 22. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: The combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem.2003; 36(6): 421-9. [ DOI:10.1016/S0009-9120(03)00078-X] 22. 23. H J, He S, Liu K, Wang Y, Shi D, Chen X. The TG/HDL-C ratio might be a surrogate for insulin resistance in Chinese non-obese women. Int J Endocrinol. 2014; 47 (16): 355-371 23. 24. Couto Alves A, Valcarcel B, Makinen VP, Morin-Papunen L, Sebert S, Kangas AJ, et al. Metabolic profiling of polycystic ovary syndrome reveals interactions with abdominal obesity. Int J Obes (Lond) . 2017; 41(9): 1331–1340. [ DOI:10.1038/ijo.2017.126] [ PMID] [ PMCID]
|